Tg Immunopharma Co., Ltd. (Tgi), A Leading Biotech Company Focused On The Development Of Novel Immuno-Oncology Therapies, Announced That The Us Fda Has Granted Clearance For The Clinical Trial Of Tgi-6, Its Groundbreaking Bispecific Antibody. Tgi-6 Targets Unique Tumour-Associated Antigens (Taa) And Cd3 Molecules Simultaneously, Enabling Potent Anti-Tumour Responses. The Antibody Demonstrates Exceptional Anti-Tumour Activity, Favourable Safety Profiles, And Remarkable Druggability.Tgi-6'S Taa Is Highly Expressed In Various Solid Tumours, Including Colorectal Cancer, Breast Cancer, Hepatocellular Carcinoma, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer, And More. This Makes Tgi-6 A Promising Candidate For The Treatment Of A Wide Range Of Solid Tumours. Preclinical Studies Have Shown Outstanding Potential, With Tgi-6 Inducing Complete Tumour Regression In Animal Models Of Colorectal Cancer Following A Single Administration. Importantly, Tgi-6 Is Designed To Maintain High Cytotoxic Activity While Minimizing The Risk Of Cytokine Release Syndrome (Crs)."We Are Thrilled To Receive Fda Clearance For The Clinical Trial Of Tgi-6," Said Professor Zhigang Tian, Founder Of Tgi And Member Of The Chinese Academy Of Engineering And The Academia Europaea. "Tgi-6 Has Demonstrated Superior Anti-Tumour Activity And Safety In Preclinical Studies. We Have Great Confidence In Its Potential As A Novel Therapy For Solid Tumours."With This Significant Milestone, Tgi Is Actively Seeking Global Partners To Collaborate On The Development, Clinical Trials, And Eventual Commercialization Of Tgi-6. By Partnering With Pharmaceutical And Biotechnology Companies, Tgi Aims To Leverage Their Expertise In Clinical Development And Market Access, Expediting The Availability Of Tgi-6 For Patients Worldwide.Tgi Remains Steadfast In Its Mission To Revolutionize Cancer Treatment Through Innovative Immunotherapies. With Fda Clearance For The Clinical Trial Of Tgi-6, The Company Is Poised To Advance The Development Of Precise Therapies For Solid Tumours. Interested Parties Are Invited To Explore Partnership Opportunities And Join Tgi In Their Pursuit Of Delivering Novel Treatment Options That Improve Patient Outcomes.Tg Immunopharma Co., Ltd. (Tgi) Is A Leading Biotech Company Dedicated To The Development Of Novel Immunotherapeutic Drugs. Focusing On Innovation And Research, Tgi Harnesses The Power Of The Immune System To Combat Cancer And Enhance Patient Outcomes.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!